LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

LLY

757.36

+3.2%↑

JNJ

151.29

+1.18%↑

UNH

291.24

+6.59%↑

ABBV

183.96

+1.27%↑

NVO

64.34

-2.56%↓

Search

Danaher Corp

Chiusa

SettoreSettore sanitario

195.99 2.8

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

188.67

Massimo

196.02

Metriche Chiave

By Trading Economics

Entrata

-132M

954M

Vendite

-797M

5.7B

P/E

Media del settore

38.921

56.602

EPS

1.88

Rendimento da dividendi

0.66

Margine di Profitto

16.617

Dipendenti

61,000

EBITDA

367M

1.8B

Raccomandazioni

By TipRanks

Raccomandazioni

Fortemente da comprare

Previsioni per 12 mesi

+26.32% upside

Dividendi

By Dow Jones

Rendimento da dividendi

Media del settore

0.66%

2.45%

Utili prossimi

22 lug 2025

Prossima data del Dividendo

25 lug 2025

Prossima data del' Ex Dividendo

27 giu 2025

Statistiche di mercato

By TradingEconomics

Capitalizzazione di Mercato

-4.4B

144B

Apertura precedente

193.19

Chiusura precedente

195.99

Notizie sul Sentiment di mercato

By Acuity

31%

69%

88 / 382 Classifica in Healthcare

Punteggio Tecnico

By Trading Central

Fiducia

Bullish Evidence

Danaher Corp Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

22 apr 2025, 10:34 UTC

Utili

Danaher 1Q Results Decline But Top Estimates

5 feb 2025, 12:54 UTC

Utili

Johnson Controls Names Weidemanis CEO, Logs 1Q Income Growth

29 gen 2025, 11:44 UTC

Utili

Danaher 4Q Revenue Rises on Gains in Life Sciences, Biotech

22 ott 2024, 10:35 UTC

Utili

Danaher 3Q EPS, Sales Top Views on Strong Cepheid Test Demand

22 apr 2025, 10:02 UTC

Utili

Danaher Still Sees 2025 Adjusted Core Revenue Up About 3% >DHR

22 apr 2025, 10:02 UTC

Utili

Danaher Sees 2025 Adj EPS $7.60-Adj EPS $7.75 >DHR

22 apr 2025, 10:02 UTC

Utili

Danaher Sees 2Q Adjusted Core Revenue Up Low-Single Digits >DHR

22 apr 2025, 10:01 UTC

Utili

Danaher: Macro Backdrop Has Become More Dynamic Since Start of Year >DHR

22 apr 2025, 10:01 UTC

Utili

Danaher 1Q Adjusted Core Revenue Flat >DHR

22 apr 2025, 10:00 UTC

Utili

Danaher 1Q Operating Cash Flow $1.3B, Adjusted Free Cash Flow $1.1B >DHR

22 apr 2025, 10:00 UTC

Utili

Danaher 1Q Adj EPS $1.88 >DHR

22 apr 2025, 10:00 UTC

Utili

Danaher 1Q EPS $1.32 >DHR

22 apr 2025, 10:00 UTC

Utili

Danaher 1Q Sales $5.74B >DHR

22 apr 2025, 10:00 UTC

Utili

Danaher 1Q Net $954M >DHR

29 gen 2025, 15:25 UTC

Discorsi di Mercato
Utili

Danaher's 2025 Sales Guidance Disappoints -- Market Talk

29 gen 2025, 13:56 UTC

Notizie principali
Utili

Danaher Had an Unusual Quarter. The Stock Is Down. -- Barrons.com

29 gen 2025, 11:08 UTC

Utili

Danaher Sees 2025 Bioprocessing Core Revenue Growth 6%-7% >DHR

29 gen 2025, 11:07 UTC

Utili

Danaher Sees 2025 Adjusted Operating Profit Margin About 28.5% >DHR

29 gen 2025, 11:07 UTC

Utili

Danaher: Expect to Return to Growth, Build Back to Normal Market Conditions in 2025 >DHR

29 gen 2025, 11:02 UTC

Utili

Danaher Sees 2025 Adjusted Core Revenue Up About 3% >DHR

29 gen 2025, 11:01 UTC

Utili

Danaher Sees 1Q Adjusted Core Revenue Down Low-Single Digits >DHR

29 gen 2025, 11:01 UTC

Utili

Danaher 4Q Operating Cash Flow $2B, Free Cash Flow $1.5B >DHR

29 gen 2025, 11:00 UTC

Utili

Danaher 4Q Adjusted Core Revenue Rose 1% >DHR

29 gen 2025, 11:00 UTC

Utili

Danaher 4Q Cont Ops EPS $1.49 >DHR

29 gen 2025, 11:00 UTC

Utili

Danaher 4Q Net $1.09B >DHR

29 gen 2025, 11:00 UTC

Utili

Danaher 4Q EPS $1.49 >DHR

29 gen 2025, 11:00 UTC

Utili

Danaher 4Q Adj EPS $2.14 >DHR

29 gen 2025, 11:00 UTC

Utili

Danaher 4Q Sales $6.5B >DHR

22 ott 2024, 10:02 UTC

Utili

Danaher 3Q Adjusted Core Revenue Rose 0.5% >DHR

22 ott 2024, 10:02 UTC

Utili

Danaher Still Sees 2024 Adjusted Core Revenue Down Low-Single Digits >DHR

Confronto tra pari

Modifica del prezzo

Danaher Corp Previsione

Obiettivo di Prezzo

By TipRanks

26.32% in crescita

Previsioni per 12 mesi

Media 241.2 USD  26.32%

Alto 265 USD

Basso 210 USD

Basato su 16 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Danaher Corp - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

16 ratings

14

Acquista

2

Mantieni

0

Vendi

Punteggio Tecnico

By Trading Central

189.8851 / 196.5Supporto e resistenza

A breve termine

Bullish Evidence

A termine intermedio

Weak Bullish Evidence

A lungo termine

Neutral Evidence

Sentiment

By Acuity

88 / 382 Classifica in Settore sanitario

Notizie sul Sentiment di mercato

Prove rialziste

Volatilità

Sotto la media

Volume delle notizie (RCV)

Sotto la media

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

$

Chi Siamo Danaher Corp

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions. The Life Sciences segment provides mass spectrometers; flow cytometry, genomics, lab automation, centrifugation, liquid handling automation instruments, antibodies and reagents, and particle counting and characterization; microscopes; protein consumables; industrial filtration products; and genomic medicines, such as custom nucleic acid products, plasmid DNA, RNA, and proteins under the ABCAM, ALDEVRON, BECKMAN COULTER, IDT, LEICA MICROSYSTEMS, MOLECULAR DEVICES, PALL, PHENOMENEX and SCIEX brands. The Diagnostics segment offers chemistry, immunoassay, microbiology, and automation systems; and molecular, acute care, and pathology diagnostics products. This segment also provides clinical instruments, reagents, consumables, software, and services for hospitals, physicians' offices, reference laboratories, and other critical care settings. The company has a research collaboration with Stanford University's Department of Bioengineering for cancer drug development. The company was formerly known as Diversified Mortgage Investors, Inc. and changed its name to Danaher Corporation in 1984. Danaher Corporation was founded in 1969 and is based in Washington, the District of Columbia.